日本批准小剂量复方坎地沙坦酯/氢氯噻嗪片上市 日本批准武田公司一日1次的小剂量复方坎地沙坦酯/氢氯噻嗪(candesartan cilexetil/hydrochlorothiazide),4mg/ 6.25mg片(Ecard LD)、8mg / 6.25mg(Ecard HD)上市,用于治疗高血压。 坎地沙坦酯系血管紧张素II抑制剂(ARB)。1999年上市,2005年成为日本首个可用于治疗慢性心力衰竭的ARB。坎地沙坦酯通过选择性阻滞许多组织(如血管平滑肌和肾上腺等)中的血管紧张素II结合于AT1受体来抑制血管紧张素II的血管收缩和醛固酮的分泌作用。氢氯噻嗪为噻嗪类利尿药,通过增加排尿减少细胞外液体容积来降低血压。Ecard为被日本高血压管理局推荐的固定小剂量ARB和利尿药的复方制剂。 【原产地英文商品名】Ecard HD(candesartan cilexetil 8mg/ hydrochlorothiazide 6.25mg)x140tabs/box Launch of ECARD® LD and ECARD® HD in Osaka, March 13 2009 – Takeda Pharmaceutical Company Limited ("Takeda") today announced that on March 13 it launched ECARD, a fixed dose combination tablet of Blopress (generic name: candesartan cilexetil) and a low-dose diuretic (generic name: hydrochlorothiazide) for treatment of hypertension. ECARD is a fixed dose combination tablet of an ARB and a diuretic, a low-dose concomitant therapy which is recommended by the Guidelines for the Management of Hypertension in . By reducing the hydrochlorothiazide dose to 6.25mg, which is a quarter of the ordinary clinical dosage, it is believed that commonly-experienced adverse events of thiazide diuretics can be lessened. An enhancement in anti hypertensive effect was also demonstrated in the phase 3 clinical trial.
“The strengths of ECARD were decided through intensive study of seeking the appropriate dosage in view of both efficacy and safety for Japanese patients with hypertension,” said Yasuhiko Yamanaka, General Manager of Pharmaceutical Marketing Division of Takeda. “We will vigorously provide medical professionals with scientific information of ECARD, as well as Blopress that is well supported by clinical evidences with Japanese, so that both products can contribute to reduce blood pressure.”
剤形
医薬品名:エカード配合錠HD 医薬品名:エカード配合錠LD |
复方坎地沙坦酯/氢氯噻嗪复方片(Ecard HD)简介:
日本批准小剂量复方坎地沙坦酯/氢氯噻嗪片上市
日本批准武田公司一日1次的小剂量复方坎地沙坦酯/氢氯噻嗪(candesartan cilexetil/hydrochlorothiazide),4mg/ 6.25mg片(Ecard LD)、8mg / 6.25mg( ... 关键字:坎地沙坦酯/氢氯噻嗪复方片剂
责任编辑:admin |
最新文章更多
推荐文章更多
热点文章更多 |